In a recent decision by a Delaware federal judge, medical diagnostics company Natera experienced a partial defeat in its patent litigation against CareDx. The judge deemed one of the three contested patents invalid, as it was found to cover patent-ineligible subject matter. This ruling marks a partial victory for CareDx in this ongoing legal battle.
Though the verdict appears to shake the stability of Natera’s patent portfolio, the remaining two patents under dispute remain unscathed. These still stand to play a crucial role in the unfolding case and, by extension, the potential market dominance of either CareDx or Natera. Both parties, engaged in the production of transplant diagnostics, have a significant stake in the outcome of the case.
For more details on the ruling, legal professionals can further explore the topic at Law360’s report on the case.